Mampuya Wambaka Ange, Matsuo Yukinori, Ueki Nami, Nakamura Mitsuhiro, Mukumoto Nobutaka, Nakamura Akira, Iizuka Yusuke, Kishi Takahiro, Mizowaki Takashi, Hiraoka Masahiro
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
J Radiat Res. 2014 Sep;55(5):934-9. doi: 10.1093/jrr/rru028. Epub 2014 May 6.
The aim of this study was to evaluate the impact of abdominal compression (AC) on outcome in patients treated with stereotactic body radiotherapy (SBRT) for primary lung cancer. We retrospectively reviewed data for 47 patients with histologically proven non-small cell lung cancer and lung tumour motion ≥ 8 mm treated with SBRT. Setup error was corrected based on bony structure. The differences in overall survival (OS), local control (LC) and disease-free survival (DFS) were evaluated to compare patients treated with AC (n = 22) and without AC (n = 25). The median follow-up was 42.6 months (range, 1.4-94.6 months). The differences in the 3-year OS, LC and DFS rate between the two groups were not statistically significant (P = 0.909, 0.209 and 0.639, respectively). However, the largest difference was observed in the LC rate, which was 82.5% (95% CI, 54.9-94.0%) for patients treated without AC and 65.4% (95% CI, 40.2-82.0%) for those treated with AC. After stratifying the patients into prognostic groups based on sex and T-stage, the LC difference increased in the group with an unfavourable prognosis. The present study suggests that AC might be associated with a worse LC rate after SBRT using a bony-structure-based set-up.
本研究旨在评估腹部压迫（AC）对接受立体定向体部放疗（SBRT）治疗的原发性肺癌患者预后的影响。我们回顾性分析了47例经组织学证实为非小细胞肺癌且肺肿瘤运动≥8 mm并接受SBRT治疗患者的数据。根据骨性结构校正摆位误差。评估总生存期（OS）、局部控制率（LC）和无病生存期（DFS）的差异，以比较接受AC治疗的患者（n = 22）和未接受AC治疗的患者（n = 25）。中位随访时间为42.6个月（范围1.4 - 94.6个月）。两组之间3年OS、LC和DFS率的差异无统计学意义（P分别为0.909、0.209和0.639）。然而，在LC率方面观察到最大差异，未接受AC治疗的患者LC率为82.5%（95%CI，54.9 - 94.0%），接受AC治疗的患者为65.4%（95%CI，40.2 - 82.0%）。在根据性别和T分期将患者分层为预后组后，预后不良组的LC差异增大。本研究表明，在基于骨性结构摆位的SBRT后，AC可能与较差的LC率相关。
